Skip to main content

Advertisement

Table 3 The prevalence of triple mutations in Pfdhfr, double mutations in Pfdhps and quintuple mutations in Pfdhfr/Pfdhps in the two cross sectional surveys according to age

From: Rapid increase of Plasmodium falciparum dhfr/dhps resistant haplotypes, after the adoption of sulphadoxine-pyrimethamine as first line treatment in 2002, in southern Mozambique

  Pfdhfr triple MT Pfdhps double MT Pfdhfr and Pfdhps quintuple MT
Age (years) Cross1 Cross2 Cross1 Cross2 Cross1 Cross2
1–5 4/12 (33.3) 16/24 (66.7) 2/12 (16.7) 11/21 (52.4) 1/10 (10.0) 8/16 (50.0)
6–14 20/43 (46.5) 24/43 (55.8) 7/46 (15.2) 17/45 (37.8) 1/31 (3.2) 8/36 (22.2)
>14 22/44 (50.0) 18/42 (42.9) 7/46 (15.2) 12/49 (24.5) 4/34 (11.8) 7/37 (18.9)
P = 0.591 0.160 0.991 0.069 0.434 0.049
  1. The donors are divided into 1–5 years, 6–14 years and above 14 years of age. Actual numbers of infections with Pfdhfr triple, Pfdhps double and Pfdhfr/Pfdhps quintuple mutations are shown out of total with the percentage of total in brackets. P: P-value of χ2-tests.